Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of the Administration of STI-3031 (Anti-PDL1) Intra-Lymphatically Using the Sofusa® DoseConnect™ DEVICE in Patients With In-Transit Melanoma (Sofusa-2)

NCT05393713 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05393713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05393713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of the Administration of STI-3031 (Anti-PDL1) Intra-Lymphatically Using the Sofusa® DoseConnect™ DEVICE in Patients With In-Transit Melanoma (Sofusa-2)
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Terminated
Start date
October 17, 2022
Completion date
February 16, 2025
Enrollment
3 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iii cutaneous melanoma ajcc v8, melanoma, metastatic melanoma, recurrent metastatic melanoma